Following a public comment period, the Federal Trade Commission has approved a final order settling charges that national kidney-dialysis chain U.S. Renal Care, Inc.’s $640 million acquisition of competitor DSI Renal from DSI Renal’s ultimate parent company, Dialysis Parent, LLC, would be anticompetitive. Under the order, first announced in December 2015, Rangers Renal Holdings LP, […]
Tag Archives: Bureau of Competition Competition
FTC Puts Conditions on Drug Manufacturer Hikma Pharmaceuticals PLC’s Proposed Acquisition of Roxane Laboratories Inc. and Boehringer Ingelheim Roxane, Inc. from Boehringer Ingelheim Corporation
Drug manufacturer Hikma Pharmaceuticals PLC will sell the rights and assets for two generic drugs, and relinquish its U.S. marketing rights to a third generic drug, in order to settle FTC charges that Hikma’s proposed $2 billion acquisition of Roxane would likely be anticompetitive. The proposed consent order preserves competition by requiring the companies to […]
FTC Approves Modified Consent Order for Mylan N.V.
The Federal Trade Commission has approved a modified final order settling charges that Mylan N.V.’s proposed hostile takeover of Perrigo Company plc would harm competition. Because Mylan failed to obtain the required threshold of Perrigo shares to succeed in its unsolicited offer, Mylan has abandoned the proposed acquisition. Accordingly, the Commission has issued a modified […]
FTC Requires Drug Marketer Hikma Pharmaceuticals PLC to Divest Rights to Five Generic Injectable Drugs as a Condition of Acquiring Certain Drug Products from Ben Venue Laboratories, Inc.
The Federal Trade Commission will require generic drug marketer Hikma Pharmaceuticals PLC to divest its rights and interests in five generic injectable pharmaceuticals, as part of a settlement resolving charges that Hikma’s $5 million acquisition of the rights to various drug products and related assets from Ben Venue Laboratories, Inc. would likely be anticompetitive. Under […]
FTC Puts Conditions on Generic Drug Marketer Lupin Ltd.’s Proposed Acquisition of Gavis Pharmaceuticals LLC
Generic drug manufacturers Lupin Ltd. and Gavis Pharmaceuticals LLC will sell the rights and assets for two generic drugs, one used to treat bacterial infections and the other to treat ulcerative colitis, in order to settle FTC charges that Lupin’s proposed $850 million acquisition of Gavis would likely be anticompetitive. The proposed consent order preserves […]
FTC Amicus Brief Urges Appeals Court to Correct District Court Holding that Proving Injury-in-Fact Is Necessary to Establish an Antitrust Violation
The Federal Trade Commission filed an amicus brief in the U.S. Court of Appeals for the First Circuit urging the court to correct the district court’s holding that a plaintiff must prove an injury-in-fact in order to establish an antitrust violation. The amicus brief, which was filed in the case of Nexium (Esomeprazole) Antitrust Litigation, […]
FTC Approves Final Order Settling Charges that Commercial Trucking Services Company Invited Competitor to Allocate Customers
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Drug Testing Compliance Group, LLC, an Idaho-based company that provides drug and alcohol testing and other services to commercial trucking companies and their drivers, illegally invited one of its competitors to enter into a customer allocation agreement. Under […]
FTC Approves Final Order Preserving Competition in Worldwide Market for RF Power Amplifiers
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that NXP Semiconductors N.V.’s $11.8 billion acquisition of Freescale Semiconductor Ltd. would likely harm competition in the worldwide market for RF power amplifiers. Under the order, first announced in November 2015, NXP is required to divest all its assets […]
FTC Approves Final Order Settling Charges that Merger of Orthopedic Practices in Berks County, Pennsylvania Would Likely Harm Competition and Inflate Prices
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that a merger combining 76 percent of the orthopedists in Berks County, PA into Keystone Orthopaedic Specialists, LLC was likely anticompetitive and violated U.S. antitrust law. The complaint also named Orthopaedic Associates, one of the six practices that merged […]
FTC Requests Public Comment on Pfizer Inc.’s Application to Modify Final Order Settling Competition Concerns Related to Pfizer’s 2009 Acquisition of Wyeth
The Federal Trade Commission is seeking public comment on an application by Pfizer Inc. to modify the FTC’s January 2010 final order, which settled the FTC’s competition concerns arising from Pfizer’s 2009 acquisition of Wyeth. The final order remedied the likely anticompetitive effects of the acquisition in numerous markets for animal health products by requiring […]